Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Bo Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0804-6404; OpenAlex author ID A5100335238. Sources: OpenAlex.

Their work

Papers
42 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 7 papers · 2022: 7 papers · 2023: 12 papers · 2024: 4 papers · 2025: 1 paper

Papers 42

  1. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  2. Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line. Co-author DOI 10.1007/s13577-024-01100-y↗
  3. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.019↗
  4. NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation. Co-author DOI 10.1186/s12885-024-11842-5↗
  5. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  6. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification. Co-author DOI 10.1007/s00432-022-04400-8↗
  7. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  8. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.03.037↗
  9. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101561↗
  10. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Co-author DOI 10.1016/j.tranon.2023.101692↗
  11. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  12. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  13. Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13102-5↗
  14. STM2457 Inhibits the Invasion and Metastasis of Pancreatic Cancer by Down-Regulating BRAF-Activated Noncoding RNA N6-Methyladenosine Modification. Co-author DOI 10.3390/cimb45110555↗
  15. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Co-author DOI 10.3390/curroncol30030228↗
  16. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Co-author DOI 10.3390/ijms24043270↗
  17. Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. Co-author DOI 10.3390/ijms24043559↗
  18. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Co-author DOI 10.1016/j.csbj.2022.07.029↗
  19. Construction of a paclitaxel-related competitive endogenous RNA network and identification of a potential regulatory axis in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101419↗
  20. Pyroptosis-related lncRNA pairs to estimate the molecular features and prognostic outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101524↗
  21. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  22. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05236-3↗
  23. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09863-z↗
  24. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12920-022-01371-0↗
  25. Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.015↗
  26. LncRNA SNHG16 contributes to tumor progression via the miR-302b-3p/SLC2A4 axis in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-020-01715-9↗
  27. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  28. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  29. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  30. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.650266↗
  31. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.674897↗
  32. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  33. LncRNA SNHG16 Contributes to Tumor Progression via miR-302b-3p/SLC2A4 in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-64744/v1↗
  34. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. Co-author DOI 10.7717/peerj.9602↗
  35. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  36. The microbiota and microbiome in pancreatic cancer: more influential than expected. Co-author DOI 10.1186/s12943-019-1008-0↗
  37. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Last author DOI 10.1111/cpr.12456↗
  38. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. First author DOI 10.7150/thno.26546↗
  39. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  40. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  41. The chemotactic interaction between CCL21 and its receptor, CCR7, facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangio… Co-author DOI 10.1007/s00534-011-0395-4↗
  42. The CXCR4-CXCL12 pathway facilitates the progression of pancreatic cancer via induction of angiogenesis and lymphangiogenesis. Co-author DOI 10.1016/j.jss.2010.03.001↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 30 shared papers, 2017–2024 · strength 4.30
  2. Jie Hua · 20 shared papers, 2019–2024 · strength 3.04
  3. Qingcai Meng · 19 shared papers, 2017–2024 · strength 2.88
  4. Si Shi · 20 shared papers, 2017–2024 · strength 2.86
  5. Jin Xu · 20 shared papers, 2017–2024 · strength 2.66
  6. Wei Wang · 14 shared papers, 2021–2024 · strength 2.27
  7. Chen Liang · 15 shared papers, 2017–2024 · strength 1.99
  8. Miaoyan Wei · 11 shared papers, 2020–2023 · strength 1.66
  9. Rong Tang · 6 shared papers, 2020–2024 · strength 0.90
  10. Siyuan Lu · 5 shared papers, 2022–2023 · strength 0.77
  11. Jin Xu · 4 shared papers, 2022–2023 · strength 0.65
  12. Jiang Liu · 5 shared papers, 2019–2021 · strength 0.59
  13. Chika Iwamoto · 3 shared papers, 2023–2025 · strength 0.55
  14. Yoshinao Oda · 3 shared papers, 2023–2025 · strength 0.55
  15. Kohei Nakata · 3 shared papers, 2023–2025 · strength 0.55
  16. Kenoki Ohuchida · 3 shared papers, 2023–2025 · strength 0.55
  17. Naoki Ikenaga · 3 shared papers, 2023–2025 · strength 0.55
  18. Jin Xu · 3 shared papers, 2022–2023 · strength 0.51
  19. Wence Zhou · 3 shared papers, 2020–2024 · strength 0.47
  20. Zhen Tan · 3 shared papers, 2020–2023 · strength 0.45
  21. Xiaomeng Liu · 3 shared papers, 2021–2023 · strength 0.43
  22. Chikanori Tsutsumi · 2 shared papers, 2024–2025 · strength 0.39
  23. Yuan Liu · 2 shared papers, 2023–2024 · strength 0.38
  24. Wenyan Xu · 5 shared papers, 2017–2019 · strength 0.37
  25. Yi Qin · 5 shared papers, 2017–2019 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.